Rocket Pharmaceuticals, Inc. (RCKT): A Bull Case Theory

We came across a bullish thesis on Rocket Pharmaceuticals, Inc. (RCKT) on Twitter by sharkbiotech. In this article, we will summarize the bulls’ thesis on RCKT. Rocket Pharmaceuticals, Inc. (RCKT)'s share was trading at $8.66 as of March 4^th.

[caption id="attachment_1231039" align="aligncenter" width="768"] A researcher studying a microscopic image of a gene therapy under a microscope.[/caption]

Rocket Pharmaceuticals (RCKT) is developing gene therapy for rare cardiac diseases, with its lead drug targeting Danon disease, a fatal condition caused by a mutation in the LAMP2 gene...